Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Lucintel | PRODUCT CODE: 1815118

Cover Image

PUBLISHER: Lucintel | PRODUCT CODE: 1815118

Equine Rhinopneumonitis Vaccine Market Report: Trends, Forecast and Competitive Analysis to 2031

PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 3 business days
SELECT AN OPTION
PDF (Single User License)
USD 3850
PDF (2 Users License)
USD 4650
PDF (5 Users License)
USD 5350
PDF (Corporate License)
USD 7050

Add to Cart

The future of the global equine rhinopneumonitis vaccine market looks promising with opportunities in the overview, veterinary pharmacy, and online sale markets. The global equine rhinopneumonitis vaccine market is expected to grow with a CAGR of 5.6% from 2025 to 2031. The major drivers for this market are the increasing prevalence of equine diseases source and the rising animal health spending & increasing uptake of animal insurance.

  • Lucintel forecasts that, within the type category, inactivated will remain the largest segment over the forecast period due to rising safety preference for inactivated vaccines due to lower risk of side effects in horses.
  • Within the application category, online sales is expected to witness the higher growth due to growing adoption of digital channels by veterinary suppliers for wider reach.
  • In terms of region, APAC is expected to witness the highest growth over the forecast period.

Emerging Trends in the Equine Rhinopneumonitis Vaccine Market

The equine rhinopneumonitis vaccine market is shaped by a combination of technological advancements, regulatory changes, and evolving consumer needs. These emerging trends are driving innovation and shaping the market in both established and emerging equine industries worldwide.

  • Combination Vaccines: There is a growing trend toward the development of combination vaccines that target multiple pathogens, including equine herpesvirus, equine influenza, and other respiratory diseases. This trend simplifies vaccination schedules and reduces the number of injections required for horses, improving overall compliance and health outcomes.
  • Advanced Vaccine Formulations: The demand for vaccines that offer longer-lasting protection against equine rhinopneumonitis is rising. Manufacturers are investing in novel adjuvants and vaccine delivery systems to increase the efficacy and duration of protection. These advanced formulations are becoming more common in the market and are expected to replace older, less effective vaccines.
  • Increased Focus on Biosecurity: With the growing risk of equine respiratory outbreaks, there is an increased focus on biosecurity and preventive health. Governments and veterinary professionals are stressing the importance of vaccination programs to prevent the spread of equine herpesvirus and other respiratory infections, particularly in regions with high equine population densities.
  • Regulatory Evolution: Regulatory standards for equine vaccines are becoming more stringent, with an increased emphasis on safety, efficacy, and traceability. This is driving innovation in vaccine production and encouraging manufacturers to develop high-quality, safer products to meet new regulatory guidelines in both developed and emerging markets.
  • Global Expansion of Vaccine Access: As the global equine market expands, there is a greater push to make vaccines accessible in developing regions. This includes improvements in vaccine distribution networks and affordability, which is helping to prevent the spread of respiratory diseases in horses worldwide, especially in emerging economies.

These emerging trends are revolutionizing the equine rhinopneumonitis vaccine market, fostering growth and creating new opportunities for vaccine manufacturers. The industry is seeing innovations that will improve vaccine efficacy, accessibility, and safety, leading to better prevention of respiratory diseases in horses across the globe.

Recent Developments in the Equine Rhinopneumonitis Vaccine Market

The equine rhinopneumonitis vaccine market has witnessed key developments aimed at enhancing the prevention of equine respiratory diseases, addressing emerging strains of viruses, and expanding vaccine accessibility worldwide.

  • Introduction of Combination Vaccines: Recent innovations have led to the development of combination vaccines that offer protection against both equine herpesvirus and equine influenza. These vaccines simplify vaccination schedules and provide broader protection, which is critical for horses involved in competitive sports and breeding programs.
  • Enhanced Vaccine Efficacy: Vaccine manufacturers have been focused on improving the efficacy of equine rhinopneumonitis vaccines. New formulations with stronger adjuvants and improved delivery mechanisms are now providing longer-lasting immunity and better protection against the virus, contributing to the overall health of the equine population.
  • Stricter Regulatory Standards: Governments and regulatory bodies worldwide are tightening vaccine approval processes to ensure higher safety and efficacy. This has led to the development of vaccines that adhere to stringent standards, helping reduce adverse reactions and ensuring better compliance with international health regulations.
  • Global Vaccine Accessibility: As demand for equine vaccines grows, efforts to expand vaccine accessibility in emerging markets have been a key development. Improved distribution networks and local vaccine production are helping increase availability in regions with previously limited access, thereby boosting preventive health practices in global equine communities.
  • Increased Research and Development Investment: Investment in research and development for equine vaccines has been on the rise, with manufacturers dedicating resources to developing vaccines that target new or evolving strains of equine herpesvirus. This ensures that the vaccines remain effective as the virus evolves, safeguarding equine populations from emerging threats.

These key developments are driving innovation and growth in the equine rhinopneumonitis vaccine market. As manufacturers enhance vaccine formulations, improve accessibility, and comply with stricter regulatory standards, the market is set for continued growth, offering better prevention against equine respiratory diseases globally.

Strategic Growth Opportunities in the Equine Rhinopneumonitis Vaccine Market

The equine rhinopneumonitis vaccine market presents significant growth opportunities across various applications, including racing, breeding, and recreational riding. Each application offers unique opportunities for manufacturers to expand their reach and improve equine health outcomes.

  • Equine Racing Industry: The equine racing industry represents a major growth opportunity due to the high value of horses in competitive sports. Ensuring the health of racehorses through vaccination is crucial, making it a priority for vaccine manufacturers to develop highly effective vaccines that protect against rhinopneumonitis and other respiratory diseases.
  • Equine Breeding: Equine breeders are investing in vaccination programs to protect breeding stock from respiratory diseases, which can affect fertility and overall reproductive health. Targeted vaccines for breeding horses offer manufacturers an opportunity to develop specialized formulations that ensure the health of both stallions and mares.
  • Recreational Riding and Leisure: As more individuals participate in recreational riding, the demand for equine health products, including vaccines, is growing. Vaccines that protect against rhinopneumonitis can help ensure the health and longevity of horses used for leisure, presenting a growing market for vaccine manufacturers.
  • Veterinary Clinics and Health Facilities: Veterinary clinics are key to the growth of the equine rhinopneumonitis vaccine market. Offering vaccines in clinics for a broad range of equine clients-both competitive and non-competitive-helps increase vaccine uptake, providing opportunities for manufacturers to expand their distribution in these healthcare settings.
  • International Markets: With the growth of equine industries in emerging economies, particularly in Asia, there is a significant opportunity for manufacturers to expand their market reach. This includes developing affordable vaccines and establishing partnerships with local distributors to increase market penetration in regions with high equine populations.

These strategic growth opportunities provide manufacturers with multiple avenues for expansion. By targeting specific equine sectors such as racing, breeding, and leisure, and focusing on improving vaccine accessibility globally, the equine rhinopneumonitis vaccine market is poised for significant growth.

Equine Rhinopneumonitis Vaccine Market Driver and Challenges

The global equine rhinopneumonitis vaccine market is driven by advancements in vaccine technology, increased awareness of equine health, and regulatory changes. However, challenges such as high vaccine costs, regulatory hurdles, and the need for continuous research to address emerging strains of the virus present obstacles to market growth.

The factors responsible for driving the equine rhinopneumonitis vaccine market include:

1. Technological Advancements in Vaccine Development: Advances in vaccine technologies, including recombinant vaccines and improved adjuvants, are driving the market by increasing vaccine efficacy and safety. These developments are making vaccines more effective in preventing equine rhinopneumonitis, encouraging wider adoption across the equine industry.

2. Increasing Demand for Equine Health Products: The rising global demand for equine health products, driven by the expansion of the equine industry, particularly in sports and recreational riding, is fueling market growth. As horse owners become more health-conscious, the demand for effective vaccines is increasing.

3. Regulatory Support and Standards: Regulatory agencies around the world are enhancing vaccine safety and efficacy standards, ensuring that only the most effective and safe products reach the market. This fosters confidence in equine vaccines, driving greater market penetration.

4. Rising Awareness of Respiratory Diseases: As equine respiratory diseases, including rhinopneumonitis, become more recognized as a significant threat to equine health, owners and veterinarians are prioritizing vaccination as part of comprehensive disease prevention strategies.

5. Growing Equine Industry in Emerging Markets: The growth of the equine industry in emerging markets, particularly in Asia and Latin America, is driving demand for equine health products, including vaccines. This provides manufacturers with a large, untapped market for equine rhinopneumonitis vaccines.

Challenges in the equine rhinopneumonitis vaccine market are:

1. High Production and Vaccine Costs: The production of vaccines, especially for specialized diseases like equine rhinopneumonitis, can be costly. High production costs, along with challenges in pricing vaccines competitively, may limit access to vaccines in price-sensitive markets.

2. Regulatory Barriers: Different regions have varying regulatory standards for equine vaccines, which can delay approval processes and increase the costs associated with vaccine development. Manufacturers must navigate these complex regulatory environments to bring vaccines to market.

3. Evolving Strains of Equine Herpesvirus: The continued evolution of equine herpesvirus poses a challenge to vaccine developers. New strains may render existing vaccines less effective, requiring ongoing research and adaptation of vaccine formulations to maintain efficacy.

The global equine rhinopneumonitis vaccine market is influenced by technological advancements, regulatory changes, and increasing awareness of respiratory diseases in horses. However, challenges like high production costs, regulatory hurdles, and evolving virus strains need to be addressed for sustained market growth.

List of Equine Rhinopneumonitis Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies equine rhinopneumonitis vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the equine rhinopneumonitis vaccine companies profiled in this report include-

  • Merck & Co
  • Esaote SPA
  • Covetrus
  • Elanco
  • Cargill

Equine Rhinopneumonitis Vaccine Market by Segment

The study includes a forecast for the global equine rhinopneumonitis vaccine market by type, application, and region.

Equine Rhinopneumonitis Vaccine Market by Type [Value from 2019 to 2031]:

    • Overview
  • Live
  • Inactivated

Equine Rhinopneumonitis Vaccine Market by Application [Value from 2019 to 2031]:

    • Overview
  • Veterinary Pharmacy
  • Online Sale
  • Others

Equine Rhinopneumonitis Vaccine Market by Region [Value from 2019 to 2031]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

Country Wise Outlook for the Equine Rhinopneumonitis Vaccine Market

The equine rhinopneumonitis vaccine market is evolving due to increasing awareness about equine respiratory diseases, including equine herpesvirus (EHV) infections. The demand for effective vaccines is growing, driven by the rising focus on equine health in both racing and recreational sectors. In this context, several developments across key markets, including the U.S., China, Germany, India, and Japan, are shaping the future of equine vaccination strategies.

  • United States: In the U.S., the equine rhinopneumonitis vaccine market has seen significant advancements, with a focus on improving vaccine efficacy against equine herpesvirus types 1 and 4 (EHV-1, EHV-4). The introduction of combination vaccines, which protect against multiple equine respiratory pathogens, is becoming increasingly popular. Additionally, the U.S. has strengthened regulatory standards for equine vaccines, encouraging more research and development into improved formulations to combat evolving strains of the virus.
  • China: China's equine rhinopneumonitis vaccine market is growing as the country's equine industry expands. Increased domestic production of vaccines has led to greater accessibility and affordability for Chinese horse owners. The Chinese government is also implementing stricter animal health regulations, which are contributing to the rising demand for vaccines. Additionally, advancements in vaccine distribution networks are ensuring that vaccines are more widely available, leading to better prevention of respiratory diseases in horses.
  • Germany: Germany has been a leader in equine veterinary care, with an emphasis on improving vaccine formulations for equine rhinopneumonitis. In recent years, there has been a push for more comprehensive and long-lasting vaccines, as well as vaccines that can be administered in combination with other equine health vaccines. Germany's well-regulated veterinary market supports high-quality research and development, which is ensuring that its equine rhinopneumonitis vaccines meet both domestic and international standards.
  • India: In India, the market for equine rhinopneumonitis vaccines is gradually growing, driven by increasing equine populations and improved awareness of equine respiratory diseases. Government initiatives to improve animal health standards and a growing interest in equine racing and recreational industries are further fueling demand. Vaccine manufacturers are focusing on making vaccines more affordable and accessible to cater to the needs of both urban and rural equine communities in India.
  • Japan: Japan's equine rhinopneumonitis vaccine market is supported by a well-established equine sector, especially in racing and sports. Vaccination is a key part of preventive healthcare for horses, and recent developments include innovations in vaccine formulations that provide broader protection against respiratory diseases. Japan is also focusing on expanding vaccine distribution systems, ensuring that rural and urban equine populations have equal access to these critical health products.

Features of the Global Equine Rhinopneumonitis Vaccine Market

  • Market Size Estimates: Equine rhinopneumonitis vaccine market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.
  • Segmentation Analysis: Equine rhinopneumonitis vaccine market size by type, application, and region in terms of value ($B).
  • Regional Analysis: Equine rhinopneumonitis vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the equine rhinopneumonitis vaccine market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the equine rhinopneumonitis vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the equine rhinopneumonitis vaccine market by type (overview, live, and inactivated), application (overview, veterinary pharmacy, online sale, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

  • 2.1 Background and Classifications
  • 2.2 Supply Chain

3. Market Trends & Forecast Analysis

  • 3.1 Macroeconomic Trends and Forecasts
  • 3.2 Industry Drivers and Challenges
  • 3.3 PESTLE Analysis
  • 3.4 Patent Analysis
  • 3.5 Regulatory Environment

4. Global Equine Rhinopneumonitis Vaccine Market by Type

  • 4.1 Overview
  • 4.2 Attractiveness Analysis by Type
  • 4.3 Overview: Trends and Forecast (2019-2031)
  • 4.4 Live: Trends and Forecast (2019-2031)
  • 4.5 Inactivated: Trends and Forecast (2019-2031)

5. Global Equine Rhinopneumonitis Vaccine Market by Application

  • 5.1 Overview
  • 5.2 Attractiveness Analysis by Application
  • 5.3 Overview: Trends and Forecast (2019-2031)
  • 5.4 Veterinary Pharmacy: Trends and Forecast (2019-2031)
  • 5.5 Online Sale: Trends and Forecast (2019-2031)
  • 5.6 Others: Trends and Forecast (2019-2031)

6. Regional Analysis

  • 6.1 Overview
  • 6.2 Global Equine Rhinopneumonitis Vaccine Market by Region

7. North American Equine Rhinopneumonitis Vaccine Market

  • 7.1 Overview
  • 7.2 North American Equine Rhinopneumonitis Vaccine Market by Type
  • 7.3 North American Equine Rhinopneumonitis Vaccine Market by Application
  • 7.4 United States Equine Rhinopneumonitis Vaccine Market
  • 7.5 Mexican Equine Rhinopneumonitis Vaccine Market
  • 7.6 Canadian Equine Rhinopneumonitis Vaccine Market

8. European Equine Rhinopneumonitis Vaccine Market

  • 8.1 Overview
  • 8.2 European Equine Rhinopneumonitis Vaccine Market by Type
  • 8.3 European Equine Rhinopneumonitis Vaccine Market by Application
  • 8.4 German Equine Rhinopneumonitis Vaccine Market
  • 8.5 French Equine Rhinopneumonitis Vaccine Market
  • 8.6 Spanish Equine Rhinopneumonitis Vaccine Market
  • 8.7 Italian Equine Rhinopneumonitis Vaccine Market
  • 8.8 United Kingdom Equine Rhinopneumonitis Vaccine Market

9. APAC Equine Rhinopneumonitis Vaccine Market

  • 9.1 Overview
  • 9.2 APAC Equine Rhinopneumonitis Vaccine Market by Type
  • 9.3 APAC Equine Rhinopneumonitis Vaccine Market by Application
  • 9.4 Japanese Equine Rhinopneumonitis Vaccine Market
  • 9.5 Indian Equine Rhinopneumonitis Vaccine Market
  • 9.6 Chinese Equine Rhinopneumonitis Vaccine Market
  • 9.7 South Korean Equine Rhinopneumonitis Vaccine Market
  • 9.8 Indonesian Equine Rhinopneumonitis Vaccine Market

10. ROW Equine Rhinopneumonitis Vaccine Market

  • 10.1 Overview
  • 10.2 ROW Equine Rhinopneumonitis Vaccine Market by Type
  • 10.3 ROW Equine Rhinopneumonitis Vaccine Market by Application
  • 10.4 Middle Eastern Equine Rhinopneumonitis Vaccine Market
  • 10.5 South American Equine Rhinopneumonitis Vaccine Market
  • 10.6 African Equine Rhinopneumonitis Vaccine Market

11. Competitor Analysis

  • 11.1 Product Portfolio Analysis
  • 11.2 Operational Integration
  • 11.3 Porter's Five Forces Analysis
    • Competitive Rivalry
    • Bargaining Power of Buyers
    • Bargaining Power of Suppliers
    • Threat of Substitutes
    • Threat of New Entrants
  • 11.4 Market Share Analysis

12. Opportunities & Strategic Analysis

  • 12.1 Value Chain Analysis
  • 12.2 Growth Opportunity Analysis
    • 12.2.1 Growth Opportunities by Type
    • 12.2.2 Growth Opportunities by Application
  • 12.3 Emerging Trends in the Global Equine Rhinopneumonitis Vaccine Market
  • 12.4 Strategic Analysis
    • 12.4.1 New Product Development
    • 12.4.2 Certification and Licensing
    • 12.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

13. Company Profiles of the Leading Players Across the Value Chain

  • 13.1 Competitive Analysis
  • 13.2 Merck & Co
    • Company Overview
    • Equine Rhinopneumonitis Vaccine Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.3 Esaote SPA
    • Company Overview
    • Equine Rhinopneumonitis Vaccine Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.4 Covetrus
    • Company Overview
    • Equine Rhinopneumonitis Vaccine Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.5 Elanco
    • Company Overview
    • Equine Rhinopneumonitis Vaccine Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing
  • 13.6 Cargill
    • Company Overview
    • Equine Rhinopneumonitis Vaccine Business Overview
    • New Product Development
    • Merger, Acquisition, and Collaboration
    • Certification and Licensing

14. Appendix

  • 14.1 List of Figures
  • 14.2 List of Tables
  • 14.3 Research Methodology
  • 14.4 Disclaimer
  • 14.5 Copyright
  • 14.6 Abbreviations and Technical Units
  • 14.7 About Us
  • 14.8 Contact Us

List of Figures

  • Figure 1.1: Trends and Forecast for the Global Equine Rhinopneumonitis Vaccine Market
  • Figure 2.1: Usage of Equine Rhinopneumonitis Vaccine Market
  • Figure 2.2: Classification of the Global Equine Rhinopneumonitis Vaccine Market
  • Figure 2.3: Supply Chain of the Global Equine Rhinopneumonitis Vaccine Market
  • Figure 2.4: Driver and Challenges of the Equine Rhinopneumonitis Vaccine Market
  • Figure 3.1: Trends of the Global GDP Growth Rate
  • Figure 3.2: Trends of the Global Population Growth Rate
  • Figure 3.3: Trends of the Global Inflation Rate
  • Figure 3.4: Trends of the Global Unemployment Rate
  • Figure 3.5: Trends of the Regional GDP Growth Rate
  • Figure 3.6: Trends of the Regional Population Growth Rate
  • Figure 3.7: Trends of the Regional Inflation Rate
  • Figure 3.8: Trends of the Regional Unemployment Rate
  • Figure 3.9: Trends of Regional Per Capita Income
  • Figure 3.10: Forecast for the Global GDP Growth Rate
  • Figure 3.11: Forecast for the Global Population Growth Rate
  • Figure 3.12: Forecast for the Global Inflation Rate
  • Figure 3.13: Forecast for the Global Unemployment Rate
  • Figure 3.14: Forecast for the Regional GDP Growth Rate
  • Figure 3.15: Forecast for the Regional Population Growth Rate
  • Figure 3.16: Forecast for the Regional Inflation Rate
  • Figure 3.17: Forecast for the Regional Unemployment Rate
  • Figure 3.18: Forecast for Regional Per Capita Income
  • Figure 4.1: Global Equine Rhinopneumonitis Vaccine Market by Type in 2019, 2024, and 2031
  • Figure 4.2: Trends of the Global Equine Rhinopneumonitis Vaccine Market ($B) by Type
  • Figure 4.3: Forecast for the Global Equine Rhinopneumonitis Vaccine Market ($B) by Type
  • Figure 4.4: Trends and Forecast for Overview in the Global Equine Rhinopneumonitis Vaccine Market (2019-2031)
  • Figure 4.5: Trends and Forecast for Live in the Global Equine Rhinopneumonitis Vaccine Market (2019-2031)
  • Figure 4.6: Trends and Forecast for Inactivated in the Global Equine Rhinopneumonitis Vaccine Market (2019-2031)
  • Figure 5.1: Global Equine Rhinopneumonitis Vaccine Market by Application in 2019, 2024, and 2031
  • Figure 5.2: Trends of the Global Equine Rhinopneumonitis Vaccine Market ($B) by Application
  • Figure 5.3: Forecast for the Global Equine Rhinopneumonitis Vaccine Market ($B) by Application
  • Figure 5.4: Trends and Forecast for Overview in the Global Equine Rhinopneumonitis Vaccine Market (2019-2031)
  • Figure 5.5: Trends and Forecast for Veterinary Pharmacy in the Global Equine Rhinopneumonitis Vaccine Market (2019-2031)
  • Figure 5.6: Trends and Forecast for Online Sale in the Global Equine Rhinopneumonitis Vaccine Market (2019-2031)
  • Figure 5.7: Trends and Forecast for Others in the Global Equine Rhinopneumonitis Vaccine Market (2019-2031)
  • Figure 6.1: Trends of the Global Equine Rhinopneumonitis Vaccine Market ($B) by Region (2019-2024)
  • Figure 6.2: Forecast for the Global Equine Rhinopneumonitis Vaccine Market ($B) by Region (2025-2031)
  • Figure 7.1: Trends and Forecast for the North American Equine Rhinopneumonitis Vaccine Market (2019-2031)
  • Figure 7.2: North American Equine Rhinopneumonitis Vaccine Market by Type in 2019, 2024, and 2031
  • Figure 7.3: Trends of the North American Equine Rhinopneumonitis Vaccine Market ($B) by Type (2019-2024)
  • Figure 7.4: Forecast for the North American Equine Rhinopneumonitis Vaccine Market ($B) by Type (2025-2031)
  • Figure 7.5: North American Equine Rhinopneumonitis Vaccine Market by Application in 2019, 2024, and 2031
  • Figure 7.6: Trends of the North American Equine Rhinopneumonitis Vaccine Market ($B) by Application (2019-2024)
  • Figure 7.7: Forecast for the North American Equine Rhinopneumonitis Vaccine Market ($B) by Application (2025-2031)
  • Figure 7.8: Trends and Forecast for the United States Equine Rhinopneumonitis Vaccine Market ($B) (2019-2031)
  • Figure 7.9: Trends and Forecast for the Mexican Equine Rhinopneumonitis Vaccine Market ($B) (2019-2031)
  • Figure 7.10: Trends and Forecast for the Canadian Equine Rhinopneumonitis Vaccine Market ($B) (2019-2031)
  • Figure 8.1: Trends and Forecast for the European Equine Rhinopneumonitis Vaccine Market (2019-2031)
  • Figure 8.2: European Equine Rhinopneumonitis Vaccine Market by Type in 2019, 2024, and 2031
  • Figure 8.3: Trends of the European Equine Rhinopneumonitis Vaccine Market ($B) by Type (2019-2024)
  • Figure 8.4: Forecast for the European Equine Rhinopneumonitis Vaccine Market ($B) by Type (2025-2031)
  • Figure 8.5: European Equine Rhinopneumonitis Vaccine Market by Application in 2019, 2024, and 2031
  • Figure 8.6: Trends of the European Equine Rhinopneumonitis Vaccine Market ($B) by Application (2019-2024)
  • Figure 8.7: Forecast for the European Equine Rhinopneumonitis Vaccine Market ($B) by Application (2025-2031)
  • Figure 8.8: Trends and Forecast for the German Equine Rhinopneumonitis Vaccine Market ($B) (2019-2031)
  • Figure 8.9: Trends and Forecast for the French Equine Rhinopneumonitis Vaccine Market ($B) (2019-2031)
  • Figure 8.10: Trends and Forecast for the Spanish Equine Rhinopneumonitis Vaccine Market ($B) (2019-2031)
  • Figure 8.11: Trends and Forecast for the Italian Equine Rhinopneumonitis Vaccine Market ($B) (2019-2031)
  • Figure 8.12: Trends and Forecast for the United Kingdom Equine Rhinopneumonitis Vaccine Market ($B) (2019-2031)
  • Figure 9.1: Trends and Forecast for the APAC Equine Rhinopneumonitis Vaccine Market (2019-2031)
  • Figure 9.2: APAC Equine Rhinopneumonitis Vaccine Market by Type in 2019, 2024, and 2031
  • Figure 9.3: Trends of the APAC Equine Rhinopneumonitis Vaccine Market ($B) by Type (2019-2024)
  • Figure 9.4: Forecast for the APAC Equine Rhinopneumonitis Vaccine Market ($B) by Type (2025-2031)
  • Figure 9.5: APAC Equine Rhinopneumonitis Vaccine Market by Application in 2019, 2024, and 2031
  • Figure 9.6: Trends of the APAC Equine Rhinopneumonitis Vaccine Market ($B) by Application (2019-2024)
  • Figure 9.7: Forecast for the APAC Equine Rhinopneumonitis Vaccine Market ($B) by Application (2025-2031)
  • Figure 9.8: Trends and Forecast for the Japanese Equine Rhinopneumonitis Vaccine Market ($B) (2019-2031)
  • Figure 9.9: Trends and Forecast for the Indian Equine Rhinopneumonitis Vaccine Market ($B) (2019-2031)
  • Figure 9.10: Trends and Forecast for the Chinese Equine Rhinopneumonitis Vaccine Market ($B) (2019-2031)
  • Figure 9.11: Trends and Forecast for the South Korean Equine Rhinopneumonitis Vaccine Market ($B) (2019-2031)
  • Figure 9.12: Trends and Forecast for the Indonesian Equine Rhinopneumonitis Vaccine Market ($B) (2019-2031)
  • Figure 10.1: Trends and Forecast for the ROW Equine Rhinopneumonitis Vaccine Market (2019-2031)
  • Figure 10.2: ROW Equine Rhinopneumonitis Vaccine Market by Type in 2019, 2024, and 2031
  • Figure 10.3: Trends of the ROW Equine Rhinopneumonitis Vaccine Market ($B) by Type (2019-2024)
  • Figure 10.4: Forecast for the ROW Equine Rhinopneumonitis Vaccine Market ($B) by Type (2025-2031)
  • Figure 10.5: ROW Equine Rhinopneumonitis Vaccine Market by Application in 2019, 2024, and 2031
  • Figure 10.6: Trends of the ROW Equine Rhinopneumonitis Vaccine Market ($B) by Application (2019-2024)
  • Figure 10.7: Forecast for the ROW Equine Rhinopneumonitis Vaccine Market ($B) by Application (2025-2031)
  • Figure 10.8: Trends and Forecast for the Middle Eastern Equine Rhinopneumonitis Vaccine Market ($B) (2019-2031)
  • Figure 10.9: Trends and Forecast for the South American Equine Rhinopneumonitis Vaccine Market ($B) (2019-2031)
  • Figure 10.10: Trends and Forecast for the African Equine Rhinopneumonitis Vaccine Market ($B) (2019-2031)
  • Figure 11.1: Porter's Five Forces Analysis of the Global Equine Rhinopneumonitis Vaccine Market
  • Figure 11.2: Market Share (%) of Top Players in the Global Equine Rhinopneumonitis Vaccine Market (2024)
  • Figure 12.1: Growth Opportunities for the Global Equine Rhinopneumonitis Vaccine Market by Type
  • Figure 12.2: Growth Opportunities for the Global Equine Rhinopneumonitis Vaccine Market by Application
  • Figure 12.3: Growth Opportunities for the Global Equine Rhinopneumonitis Vaccine Market by Region
  • Figure 12.4: Emerging Trends in the Global Equine Rhinopneumonitis Vaccine Market

List of Tables

  • Table 1.1: Growth Rate (%, 2023-2024) and CAGR (%, 2025-2031) of the Equine Rhinopneumonitis Vaccine Market by Type and Application
  • Table 1.2: Attractiveness Analysis for the Equine Rhinopneumonitis Vaccine Market by Region
  • Table 1.3: Global Equine Rhinopneumonitis Vaccine Market Parameters and Attributes
  • Table 3.1: Trends of the Global Equine Rhinopneumonitis Vaccine Market (2019-2024)
  • Table 3.2: Forecast for the Global Equine Rhinopneumonitis Vaccine Market (2025-2031)
  • Table 4.1: Attractiveness Analysis for the Global Equine Rhinopneumonitis Vaccine Market by Type
  • Table 4.2: Market Size and CAGR of Various Type in the Global Equine Rhinopneumonitis Vaccine Market (2019-2024)
  • Table 4.3: Market Size and CAGR of Various Type in the Global Equine Rhinopneumonitis Vaccine Market (2025-2031)
  • Table 4.4: Trends of Overview in the Global Equine Rhinopneumonitis Vaccine Market (2019-2024)
  • Table 4.5: Forecast for Overview in the Global Equine Rhinopneumonitis Vaccine Market (2025-2031)
  • Table 4.6: Trends of Live in the Global Equine Rhinopneumonitis Vaccine Market (2019-2024)
  • Table 4.7: Forecast for Live in the Global Equine Rhinopneumonitis Vaccine Market (2025-2031)
  • Table 4.8: Trends of Inactivated in the Global Equine Rhinopneumonitis Vaccine Market (2019-2024)
  • Table 4.9: Forecast for Inactivated in the Global Equine Rhinopneumonitis Vaccine Market (2025-2031)
  • Table 5.1: Attractiveness Analysis for the Global Equine Rhinopneumonitis Vaccine Market by Application
  • Table 5.2: Market Size and CAGR of Various Application in the Global Equine Rhinopneumonitis Vaccine Market (2019-2024)
  • Table 5.3: Market Size and CAGR of Various Application in the Global Equine Rhinopneumonitis Vaccine Market (2025-2031)
  • Table 5.4: Trends of Overview in the Global Equine Rhinopneumonitis Vaccine Market (2019-2024)
  • Table 5.5: Forecast for Overview in the Global Equine Rhinopneumonitis Vaccine Market (2025-2031)
  • Table 5.6: Trends of Veterinary Pharmacy in the Global Equine Rhinopneumonitis Vaccine Market (2019-2024)
  • Table 5.7: Forecast for Veterinary Pharmacy in the Global Equine Rhinopneumonitis Vaccine Market (2025-2031)
  • Table 5.8: Trends of Online Sale in the Global Equine Rhinopneumonitis Vaccine Market (2019-2024)
  • Table 5.9: Forecast for Online Sale in the Global Equine Rhinopneumonitis Vaccine Market (2025-2031)
  • Table 5.10: Trends of Others in the Global Equine Rhinopneumonitis Vaccine Market (2019-2024)
  • Table 5.11: Forecast for Others in the Global Equine Rhinopneumonitis Vaccine Market (2025-2031)
  • Table 6.1: Market Size and CAGR of Various Regions in the Global Equine Rhinopneumonitis Vaccine Market (2019-2024)
  • Table 6.2: Market Size and CAGR of Various Regions in the Global Equine Rhinopneumonitis Vaccine Market (2025-2031)
  • Table 7.1: Trends of the North American Equine Rhinopneumonitis Vaccine Market (2019-2024)
  • Table 7.2: Forecast for the North American Equine Rhinopneumonitis Vaccine Market (2025-2031)
  • Table 7.3: Market Size and CAGR of Various Type in the North American Equine Rhinopneumonitis Vaccine Market (2019-2024)
  • Table 7.4: Market Size and CAGR of Various Type in the North American Equine Rhinopneumonitis Vaccine Market (2025-2031)
  • Table 7.5: Market Size and CAGR of Various Application in the North American Equine Rhinopneumonitis Vaccine Market (2019-2024)
  • Table 7.6: Market Size and CAGR of Various Application in the North American Equine Rhinopneumonitis Vaccine Market (2025-2031)
  • Table 7.7: Trends and Forecast for the United States Equine Rhinopneumonitis Vaccine Market (2019-2031)
  • Table 7.8: Trends and Forecast for the Mexican Equine Rhinopneumonitis Vaccine Market (2019-2031)
  • Table 7.9: Trends and Forecast for the Canadian Equine Rhinopneumonitis Vaccine Market (2019-2031)
  • Table 8.1: Trends of the European Equine Rhinopneumonitis Vaccine Market (2019-2024)
  • Table 8.2: Forecast for the European Equine Rhinopneumonitis Vaccine Market (2025-2031)
  • Table 8.3: Market Size and CAGR of Various Type in the European Equine Rhinopneumonitis Vaccine Market (2019-2024)
  • Table 8.4: Market Size and CAGR of Various Type in the European Equine Rhinopneumonitis Vaccine Market (2025-2031)
  • Table 8.5: Market Size and CAGR of Various Application in the European Equine Rhinopneumonitis Vaccine Market (2019-2024)
  • Table 8.6: Market Size and CAGR of Various Application in the European Equine Rhinopneumonitis Vaccine Market (2025-2031)
  • Table 8.7: Trends and Forecast for the German Equine Rhinopneumonitis Vaccine Market (2019-2031)
  • Table 8.8: Trends and Forecast for the French Equine Rhinopneumonitis Vaccine Market (2019-2031)
  • Table 8.9: Trends and Forecast for the Spanish Equine Rhinopneumonitis Vaccine Market (2019-2031)
  • Table 8.10: Trends and Forecast for the Italian Equine Rhinopneumonitis Vaccine Market (2019-2031)
  • Table 8.11: Trends and Forecast for the United Kingdom Equine Rhinopneumonitis Vaccine Market (2019-2031)
  • Table 9.1: Trends of the APAC Equine Rhinopneumonitis Vaccine Market (2019-2024)
  • Table 9.2: Forecast for the APAC Equine Rhinopneumonitis Vaccine Market (2025-2031)
  • Table 9.3: Market Size and CAGR of Various Type in the APAC Equine Rhinopneumonitis Vaccine Market (2019-2024)
  • Table 9.4: Market Size and CAGR of Various Type in the APAC Equine Rhinopneumonitis Vaccine Market (2025-2031)
  • Table 9.5: Market Size and CAGR of Various Application in the APAC Equine Rhinopneumonitis Vaccine Market (2019-2024)
  • Table 9.6: Market Size and CAGR of Various Application in the APAC Equine Rhinopneumonitis Vaccine Market (2025-2031)
  • Table 9.7: Trends and Forecast for the Japanese Equine Rhinopneumonitis Vaccine Market (2019-2031)
  • Table 9.8: Trends and Forecast for the Indian Equine Rhinopneumonitis Vaccine Market (2019-2031)
  • Table 9.9: Trends and Forecast for the Chinese Equine Rhinopneumonitis Vaccine Market (2019-2031)
  • Table 9.10: Trends and Forecast for the South Korean Equine Rhinopneumonitis Vaccine Market (2019-2031)
  • Table 9.11: Trends and Forecast for the Indonesian Equine Rhinopneumonitis Vaccine Market (2019-2031)
  • Table 10.1: Trends of the ROW Equine Rhinopneumonitis Vaccine Market (2019-2024)
  • Table 10.2: Forecast for the ROW Equine Rhinopneumonitis Vaccine Market (2025-2031)
  • Table 10.3: Market Size and CAGR of Various Type in the ROW Equine Rhinopneumonitis Vaccine Market (2019-2024)
  • Table 10.4: Market Size and CAGR of Various Type in the ROW Equine Rhinopneumonitis Vaccine Market (2025-2031)
  • Table 10.5: Market Size and CAGR of Various Application in the ROW Equine Rhinopneumonitis Vaccine Market (2019-2024)
  • Table 10.6: Market Size and CAGR of Various Application in the ROW Equine Rhinopneumonitis Vaccine Market (2025-2031)
  • Table 10.7: Trends and Forecast for the Middle Eastern Equine Rhinopneumonitis Vaccine Market (2019-2031)
  • Table 10.8: Trends and Forecast for the South American Equine Rhinopneumonitis Vaccine Market (2019-2031)
  • Table 10.9: Trends and Forecast for the African Equine Rhinopneumonitis Vaccine Market (2019-2031)
  • Table 11.1: Product Mapping of Equine Rhinopneumonitis Vaccine Suppliers Based on Segments
  • Table 11.2: Operational Integration of Equine Rhinopneumonitis Vaccine Manufacturers
  • Table 11.3: Rankings of Suppliers Based on Equine Rhinopneumonitis Vaccine Revenue
  • Table 12.1: New Product Launches by Major Equine Rhinopneumonitis Vaccine Producers (2019-2024)
  • Table 12.2: Certification Acquired by Major Competitor in the Global Equine Rhinopneumonitis Vaccine Market
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!